McKesson stock trades near record territory as strong cash flow backs oncology and pharmacy growth
Published on 07/19/2026 at 11:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
McKesson stock, representing healthcare distributor McKesson Corporation (ISIN US58155Q1031), continues to be underpinned by solid fundamentals after the company reported strong recent earnings and cash generation. In its latest completed fiscal year, McKesson disclosed revenue of roughly $317 billion, highlighting its role as one of the largest pharmaceutical distributors in North America and a critical intermediary in the healthcare supply chain. That very large revenue base, combined with consistent share repurchases and rising operating income, has helped support McKesson stock near record levels over the past year, even as the broader healthcare sector navigated pricing shifts and regulatory scrutiny.
Revenue above $300 billion
According to McKesson’s investor information for its most recent full fiscal year, the company generated revenue of approximately $317 billion, up from around $281 billion in the prior fiscal year, a gain on the order of 13% year over year. This growth was driven primarily by higher pharmaceutical distribution volumes in the United States, continued expansion in specialty and oncology distribution, and contributions from its retail pharmacy and health systems businesses. The roughly $36 billion revenue increase in a single year underscores the scale at which McKesson operates and the incremental volume that can flow through its networks when prescription utilization and specialty therapies trend higher.
Alongside the top-line expansion, McKesson reported adjusted operating profit in the latest fiscal year in the mid single-digit billions of dollars, reflecting modest but steady margin improvement compared with the prior year. The combination of higher revenue and improved margins translated into strong adjusted earnings per share, which climbed by a double-digit percentage versus the previous fiscal year. This earnings progression has been a key support for McKesson stock, as investors often look at both absolute profit levels and the rate of change in EPS when assessing valuation for large, mature distributors.
Cash flow and EPS grow double digits
McKesson’s latest annual report highlighted that the company delivered operating cash flow above $10 billion in the most recently completed fiscal year, up from a level around $8 billion the year before. That roughly $2 billion increase in cash generation represents an advance of more than 20% year over year, providing additional financial flexibility for capital returns and investment in growth segments. With sizable cash inflows, McKesson has been able to repurchase a meaningful number of its shares over time, shrinking the share count and thereby amplifying growth in earnings per share.
Recent adjusted EPS figures have reflected this dynamic. For the latest completed fiscal year, McKesson reported adjusted EPS well above $25 per share, compared with a level closer to $23 per share in the prior year, a mid single-digit to low double-digit percentage increase. The EPS rise was supported by the combination of higher revenue, improved operating margins and the effect of share repurchases. As earnings growth continues, McKesson stock has been able to trade at valuation multiples that recognize both its stable cash-generating profile and its exposure to growing areas like oncology and specialty pharmacy services.
Within its capital allocation framework, McKesson has also emphasized maintaining investment-grade credit metrics and balancing debt reduction with buybacks. Net debt balances have remained manageable compared with operating cash flow, and leverage ratios are consistent with large, established distributors. This disciplined approach to capital structure helps mitigate risk for shareholders and supports the company’s ability to continue investing in technology, clinical programs and logistics infrastructure.
Oncology and specialty services expand
Beyond headline financial metrics, McKesson’s operational focus has increasingly shifted toward oncology practices, specialty pharmacy services and broader provider solutions. In recent disclosures, the company has highlighted the growth of its US Oncology Network and related services, which support community-based oncologists with drug distribution, clinical support and practice management. Revenue from oncology-related services and specialty therapeutics has grown faster than the company’s overall top line, contributing to margin resilience and diversifying McKesson’s earnings base away from purely traditional wholesaling.
McKesson also reports ongoing expansion in its prescription technology solutions and patient support services. These offerings help pharmacies and health systems manage prior authorizations, benefits coordination and adherence programs, which are increasingly important as specialty drugs carry higher price points and complex reimbursement structures. As these segments grow, they provide fee-based and service revenue that can be less sensitive to commodity-like distribution margins, supporting more stable profitability across cycles.
For investors analyzing McKesson stock, the company’s ability to combine large-scale distribution with higher-value clinical and technology services is a key part of the long-term thesis. While core distribution revenue is substantial, margin improvements often hinge on expanding specialty and service lines that carry higher returns on capital. The continued growth in oncology and specialty has therefore been a central driver behind the double-digit gains in operating cash flow and EPS seen in recent years.
Representative product and services focus
One representative area of McKesson’s business is its oncology-focused distribution and support services. Through its large network of community oncologists and integrated practice solutions, McKesson facilitates the delivery of chemotherapy agents, immunotherapies and other complex oncology treatments to patients across the United States. These services require sophisticated logistics, cold-chain management and compliance capabilities, and they generate revenue that reflects both drug volumes and value-added support.
McKesson stock price context
McKesson stock is listed on the New York Stock Exchange and has traded in recent periods near record levels, with a share price that has moved broadly in line with its earnings and cash flow growth. Over the past twelve months, the stock price has advanced in response to higher revenue, stronger EPS and a growing mix of oncology and specialty services. When compared with the company’s EPS base above $25 per share and operating cash flow above $10 billion in the latest fiscal year, the prevailing share price range reflects investor recognition of McKesson’s cash-generating capacity and its strategic positioning in the healthcare sector.
McKesson key data
- Company: McKesson Corporation
- ISIN: US58155Q1031
- Ticker: NYSE: MCK
- Trading venue: NYSE
- Sector / Industry: Health Care / Drug Wholesale and Distribution
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
